Investors of Corcept Therapeutics, Inc. (CORT) Seeking Recovery - Contact Kaplan Fox Before Deadline on April 21, 2026

Investors in Corcept Therapeutics, Inc. (NASDAQ: CORT) are urged to take action following the announcement of a class action lawsuit against the company, which has experienced significant stock price declines. The complaint, filed by Kaplan Fox & Kilsheimer LLP, represents all individuals or entities that purchased Corcept common stock between October 31, 2024, and December 30, 2025. This inquiry comes after the company revealed that the FDA issued a Complete Response Letter regarding its drug relacorilant, indicating that additional evidence of effectiveness was necessary for approval. The news led to a drastic decrease in Corcept's stock price by over 50%, dropping $35.40 per share.

According to the allegations, Corcept misrepresented the status of the relacorilant New Drug Application (NDA) during the Class Period, falsely claiming strong support for its approval and downplaying FDA concerns about the adequacy of the clinical evidence. Following the FDA's unfavorable response, investors are now facing considerable losses.

Investors whose financial interests were impacted are prompted to connect with Kaplan Fox prior to the April 21, 2026 deadline to potentially serve as lead plaintiffs in the case. However, involvement in leading the class is not a prerequisite for seeking recovery. Kaplan Fox is a well-established law firm specializing in complex litigation, with over five decades of experience in securities matters, emphasizing a track record of successful outcomes in legal actions.

The law firm encourages any investors affected by the situation to reach out for guidance on their options, providing contact details for queries. The firm underscores its intent to advocate for those impacted by the alleged mismanagement and misrepresentation by Corcept Therapeutics.

Investors in Corcept Therapeutics, Inc. (NASDAQ: CORT) are currently facing significant uncertainties following a class action lawsuit filed against the company due to allegations of misleading statements related to its lead drug candidate, relacorilant. The lawsuit claims that misrepresentations about the potential approval of relacorilant have led to a staggering 50.4% decline in the company’s stock price after the FDA issued a Complete Response Letter, indicating that the drug's efficacy evidence was insufficient.

For investors, this lawsuit highlights a critical juncture in evaluating the company’s future. As the market adjusts to these developments, potential legal ramifications and the prospect of recovery for affected shareholders must be considered. Those who acquired shares during the stated class period (October 31, 2024, to December 30, 2025) should be vigilant about their investment strategy. Joining the class action may not only provide a path to recoup losses but also signal to the market that investor cohesion exists regarding corporate governance issues.

For those looking to maintain or increase their exposure to CORT, it might be wise to adopt a cautious approach. Investors should closely monitor developments related to relacorilant’s clinical trials and any forthcoming statements from Corcept regarding its communications with the FDA. Staying informed about both the legal case and potential alternate paths for the company—such as other product candidates or pipeline developments—will be essential in shaping future investment decisions.

In summary, engaging with legal experts such as Kaplan Fox could prove beneficial for investors impacted by the stock's decline. Moreover, maintaining a comprehensive understanding of the broader market dynamics and therapeutic developments in the pharmaceutical sector will be crucial for navigating future opportunities in Corcept Therapeutics.